Oral converting enzyme inhibitor (SQ 14225) significantly reduced mean arterial pressure from 149 to 127 mmHg (P<0.02) by decreasing total peripheral resistance without changing cardiac index.
Observational (n=8)
Does the oral converting enzyme inhibitor SQ 14225 improve haemodynamics in patients with severe essential or renovascular hypertension?
The oral converting enzyme inhibitor SQ 14225 effectively lowers blood pressure by reducing peripheral resistance without compromising cardiac index, with effects enhanced by sodium restriction.
Absolute Event Rate: 127% vs 149%
p-value: p=<0.02
The haemodynamic effects of oral converting enzyme inhibitor (SQ 14225) were assessed in eight patients with severe essential or renovascular hypertension. 2. Mean arterial pressure fell (149 ± 5 to 127 ± 8 mmHg, P < 0.02), because of a fall in total peripheral resistance (6.9 ± 0.53 to 5.7 ± 0.40 kPa 1-1 s m2) without a significant change in cardiac index. Two of the eight patients were non-responders without pressure reduction or a haemodynamic change. Sodium restriction (10 mmol/day) while the same dose of SQ 14225 was continued further lowered arterial pressure (137 ± 8 to 111 ± 12 mmHg, P < 0.05) through further resistance reduction (6.5 ± 0.53 to 5.2 ± 0.40 kPa l−1 sm2, P < 0.05). 3. Haemodynamic responses to head-up tilt (increased heart rate and resistance, decreased cardiac index) were unaffected by SQ 14225 regardless of sodium intake. 4. The pattern of reduction in peripheral resistance, with unchanged cardiac index, was similar to that produced by vasodilators acting at both arteriolar and venular levels.
Cody et al. (Wed,) conducted a observational in severe essential or renovascular hypertension (n=8). oral converting enzyme inhibitor (SQ 14225) vs. baseline was evaluated on Mean arterial pressure (p=<0.02). Oral converting enzyme inhibitor (SQ 14225) significantly reduced mean arterial pressure from 149 to 127 mmHg (P<0.02) by decreasing total peripheral resistance without changing cardiac index.